Compare ADMA Biologics Inc (ADMA) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs DuPont de Nemours Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while DuPont de Nemours Inc trades at $136.69 (market cap $18.85B). The key difference: DuPont de Nemours Inc is far larger — about 8.8× ADMA Biologics Inc's market cap, and DuPont de Nemours Inc pays a 1.72% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | DD | |
|---|---|---|
Market Cap | $2.13B | $18.85B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $154.59 |
52-Week Low | $7.60 | $87.72 |
Enterprise Value | $2.20B | $21.31B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
DuPont (DD) trades at $139.61, down 0.21% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten estimates, including Q1 2026 EPS of $1.65 versus $1.44 expected, though revenue declined to $6.85B in 2025. The company executed a 3:1 reverse stock split in June 2026 and maintains dividend payments, highlighting financial restructuring efforts amid mixed segment performance.
The outlook is cautiously optimistic with a consensus price target of $227.20, implying significant upside, but risks include persistent net losses, weak Q3 guidance concerns, and macroeconomic pressures on industrial segments. Investment appeal hinges on margin improvement and successful portfolio repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
